GMED
A pretty solid way to start the year
Globus Medical came out swinging in Q1 2026. Revenue and earnings both moved sharply higher, and management pointed to a few ingredients in the recipe: continued strength in U.S. spine, margin expansion, and contributions from the Nevro acquisition. In other words, this wasn’t just “we sold more stuff” — it was “we sold more stuff and kept more of the money.”
Why investors should care
That margin piece is doing a lot of heavy lifting here. When a medtech company can grow while also expanding profitability, it usually means the business is gaining traction instead of just sprinting on a treadmill. Add in the Nevro acquisition, and you’ve got a company trying to turn scale into a real operating advantage.
The parts worth watching
- U.S. spine remains the engine under the hood.
- Margin expansion suggests the company is getting more efficient, not just bigger.
- Nevro is now showing up in the numbers, which means deal integration is moving from PowerPoint to P&L.
If Globus can keep this combo going — growth plus better margins — the stock story gets a lot more interesting. Big picture: investors love a company that can hit growth and profitability at the same time, because that’s where the market starts leaning in instead of just nodding politely.